Research programme: BBN-taxane therapeutics - Tapestry Pharmaceuticals

Drug Profile

Research programme: BBN-taxane therapeutics - Tapestry Pharmaceuticals

Alternative Names: BBN Taxane A proprietary Bombesin/paclitaxel conjugate; NBT-300

Latest Information Update: 19 Nov 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tapestry Pharmaceuticals
  • Class Paclitaxels; Peptide hormones
  • Mechanism of Action Microtubule protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Aug 2005 Suspended - Preclinical for Cancer in USA (unspecified route)
  • 04 May 2004 NaPro BioTherapeutics is now called Tapestry Pharmaceuticals
  • 21 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top